The first results of the BrighTNess trial designed to evaluate the addition of veliparib (a PARP inhibitor) plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) have been published in the The Lancet Oncology.
The efficacy analysis of 634 patients showed a higher pCR rate in the breast and lymph nodes when veliparib was added to neoadjuvant chemotherapy consisting of carboplatin plus paclitaxel compared to paclitaxel alone (53% vs 49%, p<0.0001) but not compared with patients receiving paclitaxel plus carboplatin (53% vs 58%, p=0.36). The increased toxicity of carboplatin addition (with or without veliparib) to paclitaxel was manageable and did not affect the delivery of chemotherapy. The findings support the benefit of carboplatin addition to the standard neoadjuvant chemotherapy for patients with high-risk TNBC but do not show incremental benefit of adding veliparib, at the dose and schedule used in this trial, to carboplatin-containing neoadjuvant regimens.
Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE Jr.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Lancet Oncol. 2018;19:497-509
Link in PubMed